Derma Sciences to Present at the 11th Annual Needham Healthcare Conference

PRINCETON, N.J.--(BUSINESS WIRE)-- Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care announced today that Edward J. Quilty, the Company’s chief executive officer will present a corporate overview and update at the 11th Annual Needham Healthcare Conference taking place from April 3-4, 2012 at The New York Palace Hotel, New York City. The Company’s presentation will take place on Tuesday, April 3, 2012 at 1:20 p.m. ET.

To listen and view the presentation investors may visit the investor relations section of Derma Sciences’ website at www.dermasciences.com. An archived copy of the presentation will also be available on Derma Sciences’ website.

Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings. Derma Sciences has successfully completed the Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, an investigational pharmaceutical drug under development for accelerated wound healing and scar reduction, and is preparing to begin Phase 3 clinical trials. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, BIOGUARD® for infection prevention and TCC-EZ™ total contact cast for diabetic foot ulcer healing.

For more information please visit www.dermasciences.com.



CONTACT:

Derma Sciences, Inc.
Barry Wolfenson
Executive Vice President, Global Marketing and Business Development
[email protected]
(609) 514-4744
or
Lippert/Heilshorn & Associates
Investors
Kim Sutton Golodetz ([email protected])
(212) 838-3777
or
Bruce Voss ([email protected])
(310) 691-7100
or
Media
Mackenzie Mills ([email protected])
(212) 838-3777
@LHA_IR_PR

KEYWORDS:   United States  North America  New Jersey  New York

INDUSTRY KEYWORDS:   Health  Clinical Trials  Hospitals  Medical Devices  Pharmaceutical  Other Health  Research  Other Science  Science

MEDIA:

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.